Taro Pharmaceutical Industries

Company Overview

Snapshot

Founded in June 1959, Taro Pharmaceutical Industries operates with over 1,000 employees. The company was acquired by Sun Pharma in June 2024, marking a significant milestone in its corporate trajectory.

Business overview

Taro Pharmaceutical Industries is an international pharmaceutical company specializing in the manufacturing of topical dermatological products and the development of solid drugs for cardiology and neurology. The company's core technology involves synthesizing active ingredients, providing vertical integration that ensures control over the manufacturing and quality-control process from raw materials to finished products. Taro serves the healthcare and life sciences markets, focusing on pharmaceuticals and patients within the dermatology, cardiovascular, and neurology sectors.

Strategic signal

In June 2024, Sun Pharma completed its merger with Taro Pharmaceutical Industries, following shareholder approval in May 2024. This acquisition signifies a major strategic consolidation within the pharmaceutical industry, integrating Taro's specialized product lines and manufacturing capabilities into Sun Pharma's global operations and marking a definitive exit for Taro as an independent entity.

Company Intelligence Q&A

What was the most significant corporate event for Taro Pharmaceutical Industries in 2024?

In June 2024, Sun Pharma completed its merger with Taro Pharmaceutical Industries, acquiring all outstanding shares. This followed shareholder approval in May 2024.

When did Taro Pharmaceutical Industries shareholders approve the merger with Sun Pharma?

Taro Pharmaceutical Industries shareholders approved the merger with Sun Pharma in May 2024.

What was the status of Taro Pharmaceutical Industries' financial results for the year ended March 31, 2024?

Taro Pharmaceutical Industries provided its financial results for the year ended March 31, 2024, in May 2024.

What was the outcome of the proxy advisory firms' recommendations regarding the Taro Sun Pharma merger?

In May 2024, leading independent proxy advisory firms ISS and Glass Lewis recommended that Taro shareholders vote "FOR" the Taro Sun Pharma merger.

What was the company's financial performance like for the quarter ended September 30, 2023?

Taro Pharmaceutical Industries provided its results for the quarter ended September 30, 2023, in October 2023.